Chemo- or chemo-immunotherapy remains the first line treatment of choice for patients with NSCLC with HER2 alterations, because these treatment modalities have limited activity in advanced treatment lines70. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.